Lifecare AS (DE:LFC0) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lifecare ASA has successfully completed the first phase of its longevity study for a next-generation Continuous Glucose Monitor (CGM), with no adverse tissue responses or loss of glucose sensitivity after a 12-week trial period. The study, which involves a clinical stage glucose sensor implant, showed no unexpected foreign body reactions or infections post-removal, confirming the sensor’s operational lifespan and stability. The company is now preparing to move forward with the next phase of testing after internal quality assessments.
For further insights into DE:LFC0 stock, check out TipRanks’ Stock Analysis page.
